Boundless Bio, Inc.
BOLD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | 0.03 | -0.06 | 0.30 |
| FCF Yield | -52.60% | -43.33% | -32.54% | -17.80% |
| EV / EBITDA | -3.74 | -3.87 | -6.98 | -2.01 |
| Quality | ||||
| ROIC | -9.91% | -9.35% | -9.22% | -11.32% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.75 | 0.92 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 18.59% | 8.98% | -16.58% | 22.50% |
| Safety | ||||
| Net Debt / EBITDA | -2.27 | -1.93 | -2.09 | 2.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -651.29 | -387.82 | -387.36 | -873.21 |